Drug Profile
ABL 203
Alternative Names: ABL203Latest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator ABL Bio
- Class Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Triple negative breast cancer
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for research development in Triple negative Breast-cancer in South Korea
- 10 Oct 2017 Early research in Triple negative Breast cancer in South Korea before October 2017 (ABL Bio pipeline, October 2017)